$3.60
3.49%
Nasdaq, Jul 11, 10:01 pm CET
ISIN
US75943R1023
Symbol
RLAY
Sector
Industry

Relay Therapeutics Inc Stock price

$3.60
+0.26 7.78% 1M
-1.18 24.69% 6M
-0.52 12.62% YTD
-4.16 53.61% 1Y
-15.78 81.42% 3Y
-31.45 89.73% 5Y
-31.45 89.73% 10Y
-31.45 89.73% 20Y
Nasdaq, Closing price Fri, Jul 11 2025
-0.13 3.49%
ISIN
US75943R1023
Symbol
RLAY
Sector
Industry

Key metrics

Basic
Market capitalization
$617.2m
Enterprise Value
$-93.2m
Net debt
positive
Cash
$710.4m
Shares outstanding
170.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
80.4 | 52.5
EV/Sales
negative | negative
EV/FCF
0.3
P/B
0.9
Financial Health
Equity Ratio
89.3%
Return on Equity
-43.4%
ROCE
-48.1%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$7.7m | $11.8m
EBITDA
$-361.7m | $-386.1m
EBIT
$-367.0m | $-360.6m
Net Income
$-333.4m | $-324.8m
Free Cash Flow
$-272.6m
Growth (TTM | estimate)
Revenue
-87.4% | 17.6%
EBITDA
43.3% | -5.2%
EBIT
42.9% | 3.2%
Net Income
43.3% | 3.8%
Free Cash Flow
5.2%
Margin (TTM | estimate)
Gross
-
EBITDA
-4,710.2% | -3,281.4%
EBIT
-4,778.9%
Net
-4,341.5% | -2,760.2%
Free Cash Flow
-3,550.2%
More
EPS
$-2.0
FCF per Share
$-1.6
Short interest
16.0%
Employees
261
Rev per Employee
$40.0k
Show more

Is Relay Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Relay Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Relay Therapeutics Inc forecast:

16x Buy
84%
3x Hold
16%

Analyst Opinions

19 Analysts have issued a Relay Therapeutics Inc forecast:

Buy
84%
Hold
16%

Financial data from Relay Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
7.68 7.68
87% 87%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 76 76
43% 43%
983%
- Research and Development Expense 320 320
45% 45%
4,165%
-362 -362
43% 43%
-4,710%
- Depreciation and Amortization 5.28 5.28
3% 3%
69%
EBIT (Operating Income) EBIT -367 -367
43% 43%
-4,778%
Net Profit -333 -333
43% 43%
-4,341%

In millions USD.

Don't miss a Thing! We will send you all news about Relay Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Relay Therapeutics Inc Stock News

Neutral
GlobeNewsWire
about one month ago
CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced the appointment of Claire Mazumdar, Ph.D., to the Company's Board of Directors, effective June 9, 2025.
Neutral
GlobeNewsWire
about one month ago
Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer
Neutral
GlobeNewsWire
about 2 months ago
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in two upcoming fireside chats in June: Jefferies Global Healthcare Conference on Wednesday, June 4, ...
More Relay Therapeutics Inc News

Company Profile

Relay Therapeutics, Inc. is a clinical-stage precision medicines company. It focuses on using innovative experimental and computational approaches on protein motion for making medicines against intractable precision medicine targets. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO Sanjiv Patel
Employees 261
Founded 2015
Website relaytx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today